Aarti Pharmalabs Ltd

- There are no explicit mentions of any current or future fundraising plans through debt or equity in the provided transcript. - The company discusses existing debt levels (gross debt around INR 650 crores, net debt to equity ratio expected around 0.3-0.35 post capex). - Capex projects like Atali (INR 450 crores total) and Xanthine (INR 150 crores) expansions are underway, with no direct indication of new equity or debt raising for these. - Management expects to manage capex internally, as no mention of fresh fundraises is made. - Overall, the discussion centers on operational performance, capex execution, and business growth, with no clear signals of additional fundraising plans.

- Aarti Pharmalabs plans capital expenditure (capex) for FY27-FY28 focused on expansions: - Atali site: At least one new manufacturing block is planned for FY27 with capex approval forthcoming; described as not a large capex. - Xanthine site: Approved capex is around INR150 crores for both sites combined, with an ongoing capacity increase targeting 9,000 tonnes per annum by end of Q4. - Capex at Atali includes INR450 crores total: - INR300 crores commercialized. - INR150 crores balance remaining. - Expansion plans tied to growth visibility in CDMO business, expecting strong ramp-up post-launch of new blocks. - Debottlenecking plans for steroid and oncology blocks to enhance capacity are also underway. Overall, strategic investments focus on expanding manufacturing capacity to support growing CDMO and intermediate/API businesses.

- CDMO business expected to see good growth; FY '27 guidance to be prepared post budgeting in March 2026. - Potential for substantial growth due to small base and possible 1-2 good commercial opportunities. - CDMO sales target: INR 1,000 crores; aiming for similar growth in FY '27 as FY '26. - Increasing wallet share with innovator partners; around 7-8 projects anchor 80% of CDMO sales. - New commercial molecules (from ~28 to 40) progressing to scale up revenues. - Xanthine segment planning 25-30%+ volume growth next year; with 5-10% realization improvement due to China-related dynamics. - API segment currently slow with some degrowth; expected to recover with new product launches and capacity expansion (including Atali plant). - EBITDA growth anticipated to be flat to moderate in FY '26 but with strong mid-to-long-term growth trajectory. - Expansion projects (Atali, Xanthine) to contribute progressively from FY '27 onwards.

- The company anticipates good growth in the CDMO business for FY '27, with budgeting and detailed guidance to be finalized by March. - CDMO sales target is INR 1,000 crores, with similar growth expected in FY '27 as FY '26. - EBITDA for FY '26 is expected to be largely in line with last year with marginal growth; a strong mid-to-long term growth trajectory is anticipated. - Recent margin pressures in API segment due to pricing degrowth and slow volume growth; capacity expansions and product launches are expected to aid recovery and growth. - Atali plant expansion and Xanthine plant ramp-ups projected to improve production capacity and margins progressively in FY '27. - EBITDA margins seen above 25% possible when CDMO/CMO contribution grows further. - Operational expenses from new expansions (Atali, Xanthine) may normalize once ramp-up stabilizes. - Overall, growth driven by increased wallet share in CDMO, pipeline commercializations, and capacity expansions.

- The company has single purchase orders (POs) in the range of single-digit millions of dollars, indicating sizeable orders. - At the end of FY '25, the company had 21 CDMO customers; the number is expected to increase in calendar year 2026. - A good number of new CDMO inquiries have been generated starting this year, with hopes to win multiple RFPs. - The CDMO business pipeline includes 5-7 significant projects anchoring 80% of sales, with a dynamic list of about 60 projects being tracked. - There is a mix of customers including innovators, CDMO partners, smaller biotechs, and traders. - Some projects have wallet shares of 60-70%, indicating deep involvement in product manufacturing. - Large single-product opportunities are in the pipeline, with potential turnovers exceeding INR100-150 crores. - Bulk of CDMO shipments for newer products are expected in the last quarter, reflecting order execution scaling up.